bpc-157 fda approval status 2025 approved advisory committee votes to add popular peptide to drug compounding list Hot-button peptides like BPC-157 and – bpc-157 fda approval 2025 An

The American Academy of Family Physicians and NIH identify the following clinical manifestations: Fatigue and generalized weakness Megaloblastic anemia (abnormally large, immature red blood cells) Tingling or numbness in the hands and feet (peripheral neuropathy) Difficulty walking and balance problems Cognitive disturbances including memory difficulty and confusion Mood changes, including depression and irritability Glossitis (swollen, inflamed tongue) Early symptoms such as fatigue and mild tingling are often attributed to stress, aging, or other conditions

BMC Research Notes

[11] Use is not recommended in those who are allergic to cobalt or have Leber's disease

Sep-Oct 2009;30(5):525-33